期刊文献+

原发性胆汁性肝硬化病理机制浅谈 被引量:3

A brief discussion on pathogenesis of primary biliary cirrhosis
下载PDF
导出
摘要 原发性胆汁性肝硬化(PBC)发病机制未明,研究发现同卵双生共患PBC概率较高,而其家族聚集性,全基因组关联分析(GWAS)结果皆表明了遗传因素的重要性;流行病学调查和动物模型实验则表明生物异源物质和感染性分子可能通过分子模拟在发病中起作用;而如下证据则支持其自身免疫机制:出现高度特异性的血清抗线粒体抗体(AMA)和自身反应性T淋巴细胞;就组织病理学而言,PBC的特征为汇管区炎症和免疫介导的肝内胆管破坏。从遗传因素、环境暴露、自身免疫、肝脏病理对PBC的病理机制进行了总结,指出了免疫失衡的重要性。 The pathogenesis of primary biliary cirrhosis (PBC) is unknown. Researchers have found that monozygotic twins have a higher concordance rate for PBC than dizygotic twins, and the phenomenon of familial aggregation and the results of genome - wide association stud- ies also demonstrate the importance of genetic factors in the pathogenesis of PBC. The epidemiological investigations and animal model exper- iments show that xenobiotics and infectious molecules may play a role in the pathogenesis of PBC by molecular mimicry. The appearance of highly specific serum antimitochondrial antibodies and autoreactive T cells suggests a possible autoimmune pathogenesis of PBC. The his- topathological features of PBC are inflammation in the portal area and immune - mediated intrahepatic bile duct destruction. The pathogenesis of PBC is summarized from the aspects of genetic factors, environmental exposure, autoimmune response, and fiver pathology, and the im- portance of immune imbalance is emphasized.
出处 《临床肝胆病杂志》 CAS 2013年第11期805-809,共5页 Journal of Clinical Hepatology
关键词 肝硬化 胆汁性 自身免疫疾病 疾病遗传易感性 环境暴露 病理过程 liver cirrhosis, biliary autoimmune diseases genetic predisposition to disease environmental exposure pathologic processes
  • 相关文献

参考文献5

二级参考文献45

  • 1Pornpen Thampanitchawong and Teerha Piratvisuth.Liver biopsy:complications and risk factors[J].World Journal of Gastroenterology,1999,5(4):29-32. 被引量:8
  • 2曾珍,韩玉坤,张晓峰,耿华.自身免疫性肝炎和原发性胆汁性肝硬化重叠综合征患者的临床特点[J].中华肝脏病杂志,2005,13(1):3-5. 被引量:16
  • 3WU Chi-hong WANG Qin-huan TIAN Geng-shan XU Xiao-yuan YU Yan-yan WANG Gui-qiang.Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study[J].Chinese Medical Journal,2006(3):238-241. 被引量:7
  • 4Martínez SM, Crespo G, Navasa M, et al.Noninvasive assessment of liver fibrosis.Hepatology,2011,53:325-335.
  • 5Imbert-Bismut F, Ratziu V, Pieroni L, et al.Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet,2001,357:1069-1075.
  • 6Rosenberg WM, Voelker M, Thiel R, et al.Serum markers detect the presence of liver fibrosis: a cohort study.Gastroenterology,2004,127:1704-1713.
  • 7Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.BMC Gastroenterol, 2010,10:103.
  • 8Su CW, Chan CC, Hung HH, et al.Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis.J Clin Gastroenterol,2009,43:876-883.
  • 9Corpechot C, Poujol-Robert A, Wendum D, et al.Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.Liver Int,2004,24:187-193.
  • 10Frkkil M, Rautiainen H, Krkkinen P, et al.Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.Liver Int,2008,28:787-797.

共引文献51

同被引文献37

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部